Azaya therapeutics outlicenses rights to liposomal docetaxel (AT1123) to Beijing’s CANbridge Lifescience

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. Financial details of the arrangement were not disclosed. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf

China based CANbridge life sciences has acquired exclusive development and commercialization rights to Azaya therapeutics lung cancer drug candidiate ATI-1123 for China south korea and Taiwan.

ATI-1123, is a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation.

AstraZeneca and Merck & Co Inc enter into worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775)

AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD,  today announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.